9.1 Principles of Casefinding & Facility Reference Dates
Key Takeaways
Casefinding is the systematic, continuous screening of all healthcare facility diagnostic and treatment records to identify every reportable neoplasm.
Active casefinding, in which registry staff screen source documents themselves, produces far more complete and consistent ascertainment than passive casefinding, which relies on others to report cases.
The facility reference date is the immutable baseline start date (usually January 1 of a designated year) on or after which all eligible cases must be accessioned.
The Master Patient Index (MPI), suspense files, and accession register form the foundational operational tri-file system of the cancer registry.
A case diagnosed prior to the facility reference date is non-analytic and not reportable unless the patient develops a subsequent new primary diagnosed on or after that date.
9.1 Principles of Casefinding & Facility Reference Dates
Cancer casefinding is the operational foundation of every hospital-based and population-based cancer registry. Without a rigorous, comprehensive casefinding system, an oncology registry fails to fulfill its core surveillance and clinical benchmarking missions. For the Oncology Data Specialist (ODS-C), casefinding represents the first critical checkpoint in cancer data management: the systematic screening of healthcare facility data to identify all reportable neoplasms.
Definition and Strategic Goals of Cancer Casefinding
Casefinding (also termed case ascertainment) is defined as the systematic, organized method of identifying all patients diagnosed with or receiving initial or subsequent treatment for reportable neoplastic conditions within a specified healthcare facility or geographic catchment area.
Primary Operational Objectives
- Completeness of Ascertainment: The primary objective of casefinding is capturing 100% of all reportable cases. Central registries are measured on completeness: NPCR's National Data Quality Standard and NAACCR Gold certification both require at least 95% completeness of case ascertainment. A hospital registry's casefinding is evaluated every year under its CoC Standard 6.1 quality control protocol, and it feeds the state's completeness.
- Timeliness of Identification: Identifying cases early in their diagnostic and therapeutic course allows registries to capture concurrent clinical data, submit to the Rapid Cancer Reporting System (RCRS), and prevent abstracting backlogs. CoC Standard 6.4 requires monthly submission of new and updated cases, so casefinding must also be timely.
- Data Integrity and Non-Duplication: Establishing whether a newly identified tumor represents a first lifetime diagnosis, a subsequent distinct primary malignancy, a disease recurrence, or a duplicate entry for an already accessioned patient.
Active vs. Passive Casefinding Methodologies
Healthcare facilities utilize two distinct operational models for cancer casefinding: active casefinding and passive casefinding. Understanding the operational, statistical, and staffing differences between these models is heavily emphasized on the national examination.
| Operational Dimension | Active Casefinding | Passive Casefinding |
|---|---|---|
| Primary Personnel | Credentialed Oncology Data Specialists (ODS-C) and dedicated registry casefinding staff. | Attending physicians, nursing staff, clinical unit coordinators, or health records billing personnel. |
| Mechanism | Registry staff independently and systematically query electronic source logs, disease indices, and pathology feeds. | Registry relies on external clinical departments or individual providers to voluntarily notify or transmit charts. |
| Case Completeness | High; the approach expected of accredited programs and central registries | Lower and unpredictable; under-ascertains non-surgical, outpatient and elderly cases |
| Data Consistency | High; standard reportability criteria and ambiguous terminology rules applied uniformly by specialists. | Variable and subjective; external clinicians often misinterpret in situ lesions, non-malignant CNS tumors, or skin rules. |
| Labor & Cost | Labor-intensive; requires dedicated registry FTE allocation and continuous technical workflow monitoring. | Low initial administrative cost, but high long-term audit liability and heavy post-survey corrective workloads. |
| Regulatory Acceptability | Gold standard; mandatory for CoC accreditation and standard central registry surveillance. | Unacceptable as a standalone method for accredited programs; permitted only as an adjunctive notification feed. |
Why Active Casefinding is the Standard of Care
In active casefinding, registry professionals do not wait for clinicians to report cases. The registry takes direct ownership of the surveillance net. A trained specialist navigates hospital electronic health records (EHRs), sets automated electronic laboratory triggers, audits monthly billing indices, and reconciles clinic rosters.
Conversely, passive casefinding suffers from severe selection bias. Busy clinicians frequently fail to report cases that are elderly, managed conservatively, managed palliatively without surgery, or enrolled in systemic clinical trials. In a purely passive system, the registry database skews heavily toward operative surgical cases, compromising epidemiological research and survival statistics.
The Facility Reference Date: Rules and Governance
The facility reference date is one of the most critical structural benchmarks in registry administration.
Definition
The facility reference date is defined as the formal, effective start date—almost universally established as January 1 of a designated calendar year (e.g., January 1, 2020)—on or after which all eligible reportable neoplasms diagnosed or receiving first-course therapy at the facility must be accessioned into the registry database.
FACILITY REFERENCE DATE: JANUARY 1, 2020
│
PRE-REFERENCE PERIOD │ POST-REFERENCE PERIOD (ACTIVE SURVEILLANCE)
(Diagnosed Prior to Jan 1, 2020) │ (Diagnosed On or After Jan 1, 2020)
───────────────────────────────────────────────────┼────────────────────────────────────────────────────────►
• Case diagnosed in 2018: NON-ANALYTIC / EXCLUDED │ • Case diagnosed in 2020: ANALYTIC (Class 00, 10–22)
• Admitted in 2022 for recurrence: NON-ANALYTIC │ • Diagnosed in 2023 at facility: ANALYTIC
• CANNOT be counted as an analytic case │ • Full abstraction, staging, and follow-up required
Mandatory Reference Date Rules
- Treat the Reference Date as a Stable Baseline: The CoC glossary defines the reference date simply as the "start date established for CoC accredited registries." Changing it (for example, moving it later to shrink the follow-up population) breaks trend and survival comparisons and affects the follow-up and NCDB populations, so any change needs cancer committee approval and CoC guidance. A new program must also start its registry early enough to supply a full calendar year of abstracted data before its first site visit; for example, the CoC lists a registry start date no later than January 1, 2025 for a 2027 site visit.
- Pre-Reference Date Diagnoses: A tumor diagnosed before the reference date is not an analytic case. If the program chooses to accession it, STORE assigns Class of Case 35 (diagnosed before the reference date, with initial diagnosis and all or part of first-course treatment at the facility) or Class of Case 37 (diagnosed before the reference date, with initial diagnosis elsewhere and all or part of first-course treatment at the facility). CoC does not require these nonanalytic cases.
- Subsequent Primary Exception: If a patient who was originally diagnosed prior to the reference date subsequently develops an entirely new, independent primary neoplasm diagnosed on or after the facility reference date, that subsequent primary neoplasm MUST be accessioned and abstracted as an analytic case.
- Institutional Scope: The reference date applies across all inpatient pavilions, outpatient surgical centers, and ambulatory clinics operating under the facility's hospital provider number or CoC accreditation umbrella.
The Registry Tri-File Architecture: MPI, Suspense, and Accession Register
Efficient casefinding relies on three interconnected, foundational registry filing systems:
┌─────────────────────────────────────────────────────────────────────────┐
│ THE REGISTRY CASEFINDING TRI-FILE │
└───────────────────────────────────┬─────────────────────────────────────┘
│
┌──────────────────────────────┼──────────────────────────────┐
▼ ▼ ▼
┌────────────────────────┐ ┌────────────────────────┐ ┌────────────────────────┐
│ MASTER PATIENT INDEX │ │ SUSPENSE FILE │ │ ACCESSION REGISTER │
│ • Permanent patient │ │ • Working holding queue│ │ • Indelible chronological│
│ historical database │ │ • Pending diagnostic │ │ log of all entries │
│ • Prevents duplicate │ │ confirmation/records │ │ • Unique Accession # │
│ accession numbers │ │ • Confirmed non-cases │ │ • Permanent lifetime │
│ • Tracks multiple │ │ dropped with audit │ │ identifier for │
│ primary neoplasms │ │ trail documentation │ │ patient records │
└────────────────────────┘ └────────────────────────┘ └────────────────────────┘
1. Master Patient Index (MPI)
The Master Patient Index (MPI) is a permanent, cumulative database of every patient ever accessioned into the cancer registry, spanning both analytic and non-analytic cases.
- Core Data Elements: Full legal name, maiden name/aliases, Social Security Number, medical record number (MRN), date of birth, sex, unique registry accession number, sequence numbers, primary anatomic sites, and initial diagnosis dates.
- Operational Function: Whenever a potential case is identified during screening, the ODS queries the MPI first. This search determines whether the patient is already known to the registry. If the patient exists in the MPI, the specialist evaluates whether the current clinical event represents a recurrence/metastasis of a known primary or a brand new primary tumor requiring a new sequence number.
2. The Suspense File (Suspense List)
The Suspense File is the dynamic, temporary working queue that holds potential cancer cases identified during casefinding while awaiting diagnostic confirmation, complete pathology reports, or external clinical records.
- Operational Lifecycle: A record enters suspense the moment a positive or suspicious casefinding hit occurs (e.g., an automated e-Path alert for "infiltrating ductal carcinoma" or an HIM disease index entry for "malignant neoplasm of colon").
- Case Resolution: The ODS reviews medical records in suspense:
- If the case is confirmed reportable, the specialist assigns an accession number, moves the case into the active abstracting queue, and clears the suspense item.
- If subsequent biopsy or clinical workup proves the lesion is benign or non-reportable (e.g., biopsy reveals fibroadenoma, not carcinoma), the case is dropped from suspense with an auditable justification note.
- Cases must not linger in suspense indefinitely. The registry's procedures set a review schedule (for example, a monthly aging report), and cases are followed back until they are confirmed or ruled out.
3. The Accession Register
The Accession Register is the permanent, indelible, chronological log of all cases formally accessioned into the cancer registry.
- Accession Number Structure: STORE's Accession Number–Hospital [550] is nine digits: the first four are the year the patient was first seen at the facility for a reportable tumor, and the last five are the order in which the patient was accessioned that year (for example,
202600001,202600002). - Permanence of Assignment: Once an accession number is assigned to a patient, it belongs to that patient for life. Even if the patient develops three subsequent primary cancers over the next twenty years, the accession number never changes. Multiple tumors are differentiated by the Sequence Number (e.g., Sequence 00 for a solitary primary, or Sequences 01 and 02 for consecutive primaries).
- Audit Rigor: An accession number can never be reassigned to another patient. If a case is accessioned in error and later voided upon discovery of a misdiagnosis, the accession number is retired with a documented void entry in the register to preserve the numerical sequence audit trail.
Practice Scenario & Exam Pitfalls
Clinical Practice Scenario
A 68-year-old male was diagnosed with invasive adenocarcinoma of the rectosigmoid colon at St. Jude Hospital on August 14, 2018, where he underwent a low anterior resection. St. Jude Hospital established its cancer registry with a facility reference date of January 1, 2020. On March 12, 2026, the patient presents to St. Jude Hospital with metastatic recurrence in the liver and begins systemic FOLFOX chemotherapy. The registry supervisor asks the ODS whether this patient should be accessioned as an analytic case for the 2026 reporting year.
ODS Regulatory Analysis: The original primary malignancy was diagnosed on August 14, 2018, which is prior to the facility reference date of January 1, 2020. Under CoC and standard registry rules, a case diagnosed prior to the facility reference date cannot be accessioned as an analytic case, even if the patient receives treatment for recurrence at the facility after the reference date. The patient's 2026 chemotherapy represents treatment for recurrence of a pre-reference primary. If the program chooses to accession it, it is nonanalytic Class of Case 35 (diagnosed at the facility before the reference date). It is not required by CoC and cannot be counted toward the facility's analytic caseload. However, if this patient had developed a completely new primary (such as squamous cell carcinoma of the lung in 2026), that new lung primary would be fully reportable as an analytic case.
Core Exam Pitfalls to Avoid
- Pitfall 1: Treating the reference date as a convenience setting. The reference date defines which cases are analytic for NCDB submission and follow-up. It is not changed casually, and pre-reference-date cases stay nonanalytic (Class of Case 35 or 37) even if they return for treatment.
- Pitfall 2: Confusing the Accession Number with the Sequence Number. The accession number identifies the patient chronologically based on their first encounter year; the sequence number identifies the specific primary tumor across the patient's lifetime.
- Pitfall 3: Failing to maintain an audit trail for dropped suspense cases. Suspense records that are determined to be non-reportable should not simply be deleted without documentation. Maintaining an auditable record of why a case was dropped prevents repeated screening re-entries and satisfies quality control reviews.
Which operational characteristic distinguishes active casefinding from passive casefinding in a hospital-based cancer registry?
Active casefinding relies entirely on voluntary case notifications routed from attending clinical physicians.
Active casefinding is conducted directly by trained registry staff who systematically review source documents and logs, rather than waiting for others to report cases.
Active casefinding is permitted only in central population-based registries, whereas hospital registries must use passive reporting.
Active casefinding restricts screening exclusively to surgical pathology reports and excludes medical billing disease indices.
A hospital cancer registry established its facility reference date as January 1, 2022. In February 2026, a patient who was diagnosed with invasive breast carcinoma at the facility in September 2020 presents with widespread bone metastases and initiates palliative radiation therapy. How should the Oncology Data Specialist handle this case under Commission on Cancer reference date rules?
Accession the patient as an analytic case because first-course radiation therapy was administered after the reference date.
Change the facility reference date retroactively to January 1, 2020, to allow accessioning of the breast cancer.
Do not accession the breast cancer as an analytic case because the initial primary diagnosis occurred prior to the facility reference date.
Accession the bone metastases as a new primary malignancy diagnosed in 2026 with an analytic sequence number.
What is the primary function of the cancer registry Suspense File, and what is the required operational protocol when a suspense case is determined to be non-reportable?
It serves as a temporary working repository for potential cases pending complete diagnostic confirmation; non-reportable cases are removed with an auditable documentation note.
It archives permanently closed abstracts that have completed active 5-year follow-up; non-reportable cases are transmitted to the National Cancer Database.
It functions as a secure backup for the Master Patient Index; non-reportable cases are reassigned a new chronological accession number.
It stores duplicate patient abstracts identified during data quality audits; non-reportable cases are automatically reported to the state health department.
Sections you finish are checked off in the contents.